Imagine looking up at the night sky, not just to gaze at stars, but to witness a nightly procession of specialized spacecraft returning to Earth, each carrying invaluable cargo: life-saving pharmaceuticals manufactured in the pristine environment of space. This isn’t a scene from a distant sci-fi novel; it’s the near-future vision championed by Will Bruey, CEO of Varda Space Industries. Bruey, drawing from his engineering experience at SpaceX, believes this reality is not decades away, but within the next 10 years.
A Glimpse into the Future: Faster, Cheaper, Better Drugs
Bruey’s audacious predictions are rooted in observing the rapid evolution of space technology. He recalls working on early Falcon 9 rockets, where the concept of ubiquitous reusable rockets seemed like a far-off dream. Today, that dream is a daily reality, with hundreds of successful missions. "If someone had told me ‘reusable rockets,’ and ‘[we’ll see as] many [of these] flights as daily flights out of LAX,’ I would have been like, ‘All right, [maybe in] 15 to 20 years,’" Bruey shared at a recent TechCrunch event. "And this feels the same level of futuristic."
Varda Space Industries isn’t just talking about the future; they’re actively building it. In February 2024, after navigating a complex regulatory landscape, Varda achieved a historic milestone. They became only the third corporate entity ever to successfully bring a manufactured product from orbit back to Earth – specifically, crystals of ritonavir, an HIV medication. This exclusive club currently includes aerospace giants like SpaceX and Boeing. Varda has since completed several more missions, demonstrating a repeatable process.
The Science of Space-Made Crystals: Why Microgravity Matters
The core of Varda’s innovation lies in harnessing the unique properties of microgravity for pharmaceutical manufacturing. On Earth, gravity exerts constant influence, affecting how molecules arrange themselves and how crystals grow. This can lead to imperfections, inconsistencies, and limitations in the final product. In space, however, these forces are virtually eliminated.
"In microgravity, the usual forces that interfere with crystal formation on Earth – like sedimentation and gravity pulling on growing crystals – essentially disappear," explains Varda. This allows for unprecedented control over the crystallization process. Varda can precisely guide the formation of crystals, ensuring uniform sizes and even creating novel polymorphs – different structural arrangements of the same molecule. These advancements are not merely academic; they translate into tangible benefits for drugs: enhanced stability, superior purity, and a significantly longer shelf life.
The process, while not instantaneous – pharmaceutical manufacturing in orbit can take weeks or months – is designed for efficiency once the production phase is complete. Varda’s W-1 capsule, a compact, conical spacecraft roughly the size of a large kitchen trash can, detaches from its orbital host. It then endures a fiery reentry through Earth’s atmosphere at speeds exceeding Mach 25, protected by a robust heat shield developed by NASA. Finally, a parachute ensures a gentle landing, delivering its precious cargo safely back to Earth.
Beyond the Hype: The Business of In-Space Manufacturing
Bruey emphasizes a crucial distinction: Varda isn’t just "in the space industry"; they are building an "in-space industry." Space, in their view, is simply another accessible location for production. The business itself, he argues, is fundamentally prosaic. He likens their orbital manufacturing facilities to advanced ovens, equipped with familiar controls for temperature, stir rate, and pressure, but with the crucial addition of a "gravity knob."
"Forget about space for a second," Bruey suggests. "We just have this magic oven in the back of our warehouse where you can create formulations that you otherwise couldn’t."
It’s important to note that Varda isn’t focused on discovering new drugs or synthesizing entirely new molecules. Their ambition lies in expanding the capabilities of existing, approved pharmaceuticals. This approach is grounded in proven science. Major pharmaceutical players like Bristol Myers Squibb and Merck have conducted crystallization experiments on the International Space Station for years, validating the concept. Varda’s contribution is in building the reliable, scalable infrastructure to bring this potential to a commercial reality.
The Accelerating Factors: Why Now?
Several key developments have converged to make Varda’s vision achievable: the increasing predictability and affordability of space launches, and the emergence of off-the-shelf spacecraft buses.
"Ten years ago, you would have had to get a chartered flight. It was like hitchhiking to get to orbit if you were not a primary mission payload," Bruey explains. "It’s still expensive today, but [it’s dependable, you can book a slot, and we [have] booked launches years in advance."
The availability of components like Rocket Lab’s Photon satellite buses has been a significant enabler. Varda can integrate its pharmaceutical manufacturing capsules with these readily available orbital platforms, streamlining the development and deployment process.
The ‘Seven Domino Theory’: A Chain Reaction for Lower Costs
Bruey often articulates his vision through a compelling framework he calls the "seven domino theory" when engaging with policymakers. The first domino, reusable rockets, has already fallen, thanks to companies like SpaceX. The second is Varda’s core operation: manufacturing drugs in orbit and returning them to Earth.
The third domino, and arguably the most significant, is the initiation of clinical trials for space-manufactured drugs. This signifies a crucial shift towards "perpetual launch." Unlike traditional satellite companies that invest in hardware for a fixed objective, Varda’s business model inherently requires ongoing launches to meet demand.
"Each drug formulation requires manufacturing runs. Manufacturing runs require launches. More demand for the drugs means more launches," Bruey highlights. This continuous demand fundamentally alters the economics for launch providers. Instead of one-off capital investments, they gain a customer with potentially limitless, growing demand. This predictable, scalable demand justifies the fixed costs of launch infrastructure and drives down per-launch prices.
This leads to the fourth domino: as Varda scales its operations, costs inevitably decrease. This reduction in cost makes the next tier of drugs economically viable, creating a virtuous cycle. More drugs manufactured lead to further scaling and even lower costs, a feedback loop Bruey believes will "shove launch costs into the ground."
The long-term implications are profound. While Varda’s commercial viability is still being proven, and no space-manufactured drugs are yet on pharmacy shelves, the envisioned reduction in launch costs will unlock space for numerous other industries. Semiconductors, fiber optics, and advanced materials – any sector that benefits from microgravity but has been deterred by prohibitive costs – will see new opportunities emerge.
Ultimately, Bruey foresees a future where the cost of sending a human to orbit for a month becomes less expensive than keeping them on Earth, particularly when factoring in the expense of developing advanced automation. He paints a picture of individuals like "Jane" spending a month in space, working in a pharmaceutical factory, akin to an oil rig worker. This, he believes, will be the moment when "the invisible hand of the free market economy lifts us off our home planet."
The Near-Death Experience: Navigating Regulatory Hurdles
The path to Varda’s current success was far from smooth. Bruey recounted a near-fatal setback with their first mission, W-1. Launched in June 2023, the capsule successfully manufactured ritonavir crystals in orbit. However, the return journey hit a significant roadblock: regulatory approval for landing.
The intended landing site, the Utah Test and Training Range, is primarily used for military testing. Space pharmaceuticals, at that time, did not fit neatly into their established priorities. Varda’s scheduled landing windows were repeatedly bumped by higher-priority military missions. Each delay invalidated the company’s reentry license with the FAA, forcing them to restart the arduous approval process.
"There were 80 people in the office who had spent two and a half years of their lives on this thing, and it’s in orbit, but we’re not sure if it can come home," Bruey recalled, describing the immense pressure and uncertainty.
Externally, the situation might have appeared as recklessness. However, Bruey clarified that the FAA had, in fact, authorized Varda to launch without a fully finalized reentry license, aiming to foster the nascent commercial reentry industry. The agency encouraged Varda to coordinate the license and range usage while the capsule was already in orbit.
The true challenge was the novelty of the situation. This was the first commercial land reentry on a military test range. There was no established protocol for coordinating between the range and the FAA, leading to concerns about liability on both sides.
Varda explored various alternatives, including water landings (which proved unsuitable due to the capsule’s design) and potential landings in Australia. Bruey, however, remained resolute. "Either you have to push the boundaries of regulation to create this future, or you don’t," he stated. "In order for Varda to be successful, we need to land on land regularly. So we just sucked it up and said, ‘Let’s figure this one out.’"
While their first capsule remained in orbit, Varda continued its work, producing the next capsule and hiring staff. Finally, in February 2024, eight months after its launch, the W-1 capsule successfully landed at the Utah Test and Training Range. This marked a significant achievement: the first commercial spacecraft to land on a military test range and the first to land on U.S. soil under the FAA’s Part 450 licensing framework, designed to enhance flexibility for commercial space operations.
A New Frontier: Hypersonic Testing and Future Potential
Necessity, it seems, has also birthed a secondary business for Varda: hypersonic testing. The extreme speeds and conditions of reentry (Mach 25) create a unique, scientifically valuable environment that is difficult to replicate on Earth. Temperatures can reach thousands of degrees, and the air itself undergoes significant chemical reactions, forming a plasma sheath around the vehicle.
Defense agencies are eager to test materials, sensors, and navigation systems under these real-world hypersonic conditions. Traditionally, this required highly expensive, dedicated test flights. Varda’s W-1 capsules, however, naturally achieve these speeds during reentry. The company can now embed sensors or test new thermal protection materials within the capsule, effectively turning the reentry into a valuable scientific experiment.
"The capsule is akin to a wind tunnel, and the reentry is the test," Bruey explained. Varda has already conducted successful experiments for the Air Force Research Laboratory, including payloads designed to take in-situ measurements of the plasma layer during reentry.
Investor Confidence and the Road Ahead
These groundbreaking achievements have not gone unnoticed by investors. Varda has secured substantial funding, raising $329 million as of its Series C round. A significant portion of this capital is designated for expanding its pharmaceutical lab in El Segundo and for hiring specialized scientists, including structural biologists and crystallization experts. The company is looking to tackle increasingly complex molecules, with an eye on the lucrative biologics market, such as monoclonal antibodies, a sector valued at $210 billion.
Of course, a great deal of work remains. Varda faces the challenge of not only breaking into the highly competitive pharmaceutical market but also scaling its operations to meet demand and prove its long-term commercial viability. However, if Will Bruey’s vision holds true, the future he describes is not a distant dream but a rapidly approaching reality, fundamentally altering how we develop and access essential medicines, and indeed, how humanity expands its presence beyond Earth.